Neumora Therapeutics, Inc. (NMRA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.39
- As of
Kresmion compiles this page from NMRA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Neumora Therapeutics, Inc. (NMRA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-14.
See the full NMRA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NMRA on one page. Preview it with sample data, then open it live with a free account.
Preview the NMRA dossierActive events for NMRA
- high13F: funds added
3 tracked funds increased NMRA this 2026Q2, institutional consensus
- mediumEarnings above estimates
Q2-2026: Beat consensus by 6.0%, EPS $-0.23 vs $-0.2448 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +619% to NMRA (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +1115% to NMRA (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +6585% to NMRA (2026Q2)
FREE, NO ACCOUNT
Every event on NMRA, as it fires
You are seeing 5 of 12 events recorded on NMRA since 2026-05-17.
The five above landed across 3 days. The other 7 were recorded on 2 other days. 6 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NMRA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 640979100 · 2026Q2 | $3.8M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 640979100 · 2026Q2 | $2.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 640979100 · 2026Q2 | $1.4M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 640979100 · 2026Q2 | $866K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NMRA
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
NMRA against its peers
NMRA's return on equity of -228.1% ranks in the 17th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-04-30.
| Metric | NMRA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 2.7M | n/a | 12 |
| Gross margin | n/a | 66.9% | n/a | 7 |
| Operating margin | n/a | -193.1% | n/a | 11 |
| Net margin | n/a | -190.6% | n/a | 12 |
| Return on equity | -228.1% | -84.1% | 17 | 20 |
Peers (24): RANI, PMN, NTRB, CRDF, MAIA, MNOV, CSBR, OKYO, CING, CGTX, ACRV, PDSB, EQ, CRBP, SPRO, PTHS, TENX, HYFT, AURX, MIST, FBIO, ONCY, RNXT, XBIT. Left out: TELO (no annual filing). Fiscal periods ending between 2025-03-31 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (NMRA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow NMRA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to NMRA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.